Ten biotech investors back Singapore startups in 2026. Novo Holdings and OrbiMed lead institutional biopharma rounds. Temasek Life Sciences and A*STAR anchor early-stage research commercialization. Singapore's Biopolis is the top biotech cluster in Southeast Asia.
Singapore's Biopolis at one-north houses 50+ biotech companies and 7,000 researchers. No other Southeast Asian city gives biotech founders this density of scientific and investor access.
A*STAR and Temasek Life Sciences provide non-dilutive co-funding before VC capital enters. Founders who tap these programs reach IND-enabling studies at significantly lower equity cost.
Singapore-incorporated biotech companies get recognition in FDA, EMA, and TGA filings. HSA-approved biotech programs are accepted by major regulatory authorities with shorter review timelines.
This guide covers 10 active biotech investors in Singapore writing cheques in 2026.
| Type | Check size | Sector focus | Website | |
|---|---|---|---|---|
| Novo Holdings | Life science VC | $10M-$100M | Pharma, biotech, digital health | novoholdings.dk |
| OrbiMed | Biotech VC | $10M-$100M | Biopharma, med devices, diagnostics | orbimed.com |
| Vickers Venture Partners | Deeptech VC | $2M-$20M | Biotech, deeptech, life sciences | vickersventure.com |
| EDBI | Gov strategic VC | $5M-$50M | Biotech, medtech, life sciences | edbi.com |
| Temasek Life Sciences Accelerator | Corp incubator/VC | $1M-$20M | Biotech, genomics, plant biotech | temaseklifesciencesaccelerator.com |
| Heritas Capital | Healthcare PE/VC | $5M-$50M | Healthcare, biotech, life sciences | heritascapital.com |
| A*STAR Ventures | Gov research VC | $500K-$10M | Deep biotech, AI health, genomics | astar.edu.sg |
| Pavilion Capital | Temasek PE | $20M-$100M | Healthcare, biotech, life sciences | pavilioncap.com |
| Openspace Ventures | Seed to Series B | $2M-$15M | Biotech, healthtech, digital health | openspace.vc |
| InnoVen Capital | Venture debt | $2M-$15M | Growth-stage biotech and medtech | innovencapital.com |
Track your Singapore biotech investor pipeline
Ellty shows who opened your pitch and when. Follow up while VCs are reviewing your scientific data.
Start free 14-day trialWhat Singapore biotech VCs look for
Singapore biotech VCs want peer-reviewed publications or IND-enabling study data. Founders without scientific publications face a harder path to institutional biotech capital.
IP ownership and freedom to operate analysis are reviewed before any term sheet. Clean IP with Singapore or US patent applications signals VC-grade biotech from day one.
Organize your IP documents and scientific data in a secure file sharing platform from day one. Biotech diligence involves patent attorneys, clinical advisors, and financial reviewers.
ASEAN market size alone doesn't justify biotech VC in Singapore. Biopharma investors want FDA or EMA approval pathways - global therapeutic ambitions are expected.
Singapore biotech founders who start at Biopolis with an A*STAR research collaboration and peer-reviewed data attract global institutional investors 2 years faster than founders who start in isolation.
10 Singapore biotech investors
1. Novo Holdings
Novo Nordisk's investment arm with Singapore entity and the deepest Biopolis network.
Recent Deals: Singapore biotech investments 2025-2026; Biopolis precinct active; 5 APAC deals closed
LinkedIn: Novo Holdings LinkedIn
Sector Focus: Biotech, pharma, life sciences
Stage Focus: Series A to growth
Location: Singapore
Website: novoholdings.dk
2. OrbiMed
New York biotech fund with Singapore office and the strongest Asia clinical-stage network.
Recent Deals: Clinical-stage biotech investments 2025; Singapore and APAC portfolio; IND-ready companies backed
LinkedIn: OrbiMed LinkedIn
Sector Focus: Biotech, clinical-stage, oncology
Stage Focus: Series B to growth
Location: Singapore
Website: orbimed.com
3. Vickers Venture Partners
Singapore-based deep tech VC with biotech and medtech Biopolis network connections.
Recent Deals: Biotech and deep tech investments 2025; Biopolis precinct network connections actively maintained
LinkedIn: Vickers Venture Partners LinkedIn
Sector Focus: Biotech, medtech, deep tech
Stage Focus: Seed to Series B
Location: Singapore
Website: vickersventure.com
4. EDBI (EDB Investments)
Singapore government's corporate fund - best for biotech seeking Biopolis co-location.
Recent Deals: Singapore biotech government investments 2025-2026; Biopolis and EDB incentive program active
LinkedIn: EDBI (EDB Investments) LinkedIn
Sector Focus: Biotech, pharma, life sciences
Stage Focus: Series A to growth
Location: Singapore
Website: edbi.com.sg
5. Temasek Life Sciences Accelerator
Temasek-backed accelerator with direct pipeline to Singapore pharma and CRO network.
Recent Deals: Singapore biotech accelerator investments 2025-2026; Temasek pharma network connections active
LinkedIn: Temasek Life Sciences Accelerator LinkedIn
Sector Focus: Biotech, life sciences, pharma
Stage Focus: Pre-seed to Series A
Location: Singapore
Website: tls.com.sg
6. Heritas Capital
Single-family office with deep biotech and life sciences investment mandate in Singapore.
Recent Deals: Singapore biotech and life sciences investments 2025; family office network active for startups
LinkedIn: Heritas Capital LinkedIn
Sector Focus: Biotech, life sciences, healthtech
Stage Focus: Seed to Series B
Location: Singapore
Website: heritas.com
Track who's reading your Singapore biotech pitch
Ellty shows you which biotech VCs opened your deck and how long they spent on each slide.
Start free 14-day trial7. A*STAR Ventures
Singapore's research agency CVC with direct Biopolis lab access and commercialization.
Recent Deals: A*STAR biotech spin-outs 2025-2026; Biopolis commercialization and IP licensing active
LinkedIn: A*STAR Ventures LinkedIn
Sector Focus: Biotech, research, life sciences
Stage Focus: Seed, Series A
Location: Singapore
Website: a-star.edu.sg
8. Pavilion Capital
Temasek-backed fund with active biotech and healthcare portfolio in Singapore and APAC.
Recent Deals: Singapore and APAC biotech investments 2025; Temasek healthcare portfolio network active
LinkedIn: Pavilion Capital LinkedIn
Sector Focus: Biotech, healthcare, life sciences
Stage Focus: Series A to growth
Location: Singapore
Website: pavilion-capital.com
9. Openspace Ventures
Southeast Asia's most active biotech and healthtech fund with clinical trial network.
Recent Deals: SEA biotech investments 2025; clinical trial and hospital network connections in 6 SEA markets
LinkedIn: Openspace Ventures LinkedIn
Sector Focus: Biotech, healthtech, diagnostics
Stage Focus: Seed, Series A
Location: Singapore
Website: openspace.vc
10. InnoVen Capital
Singapore's leading venture debt for biotech at Series B+ with Biopolis experience.
Recent Deals: Venture debt for Series B+ biotech 2025-2026; Singapore, India and China portfolio active
LinkedIn: InnoVen Capital LinkedIn
Sector Focus: Biotech, venture debt, growth
Stage Focus: Series B to growth
Location: Singapore
Website: innovencapital.com
Biopolis: Singapore's biotech cluster
Biopolis at one-north is home to A*STAR institutes, global pharma R&D, and 50+ biotech startups. Being at Biopolis gives founders daily access to the scientists who become their first collaborators.
Pfizer, GSK, Takeda, and Novartis all have Singapore R&D operations at Biopolis. Pharma R&D partnerships from Biopolis convert to licensing deals and co-development agreements faster than anywhere else in Asia.
Manage your pharma partnership and investor documents through an investor portal to control access per stakeholder. Biotech deals involve pharma partners, co-investors, and lawyers with different document needs.
JTC provides subsidized lab space at Biopolis for qualifying Singapore biotech startups. Apply to JTC's LaunchPad program before signing a commercial lease - it cuts burn by S$8K-$20K per month.
Singapore biotech grant landscape
A*STAR's Industry Alignment Fund provides up to S$2M for biotech proof-of-concept projects. Apply before your seed round - this grant creates scientific data that replaces expensive pilot studies.
NMRC's Translational and Clinical Research programs fund Singapore clinical trials directly. NMRC grants eliminate 30-40% of Phase 1 trial costs for qualifying Singapore biotech companies.
Store your grant documentation and investor materials in a startup data room from day one. Grant applications create IP records and regulatory filings that become VC due diligence evidence.
SINGA scholarships fund PhD candidates to work in your Singapore biotech company. This provides subsidized scientific talent at government cost - a structural advantage over biotech in most other markets.
Singapore vs Boston for biotech
Singapore has faster early regulatory feedback than the US - HSA pre-submission meetings are free. Boston biotech companies wait 6-12 months for FDA pre-IND meetings; Singapore gets HSA response in 6 weeks.
Boston has a deeper pool of clinical-stage biotech capital than Singapore. Singapore is better for pre-clinical through Phase 1 proof-of-concept; Boston for Phase 2 and beyond.
Track your dual-market fundraising with a pitch tracking tool to coordinate Singapore and US VC conversations. Many Singapore biotech rounds include a Boston or NYC co-investor alongside Novo or Pavilion.
Singapore manufacturing infrastructure - ALPS, Lonza Singapore - is world-class. Biotech companies with Singapore CMO relationships get US FDA approval faster than those without GMP proof.
How to pitch a Singapore biotech investor
Lead with peer-reviewed data and IP status. Both filter out 90% of early-stage biotech applicants.
- 1.Publish peer-reviewed scientific data firstA Nature or Cell paper opens every Singapore biotech VC door in weeks, not months.
- 2.Apply to A*STAR co-funding before seed raiseA*STAR grants fund IND-enabling studies without equity. Apply 6 months before raising.
- 3.Get freedom-to-operate IP legal opinionA clean FTO analysis costs S$15K-$40K but prevents VC diligence failures later.
- 4.Share scientific deck via Ellty and track opensKnow when VCs review your data. Follow up within 24 hours of their session.
- 5.Follow up once after 14 business daysBiotech VCs deliberate longer than tech VCs. One clear follow-up is enough.
How Ellty helps you land a biotech investor in Singapore
Ellty is a data room for biotech founders. Track VC interest and follow up at the right time.
- 1.Organise your biotech fundraising documentsAdd deck, scientific data, and IP documents. Set access per investor group.
- 2.Share trackable links with Singapore VCsSend each VC a unique link. Ellty logs every open and time on each section.
- 3.Follow up when VCs are reviewing your scienceSee which VCs opened your data files today. Follow up within 24 hours.
Singapore biotech investors: common questions
- Seed rounds run $1M-$5M. A*STAR and TLSA co-invest from pre-seed stage.
- Oncology, genomics, digital therapeutics, and infectious disease lead Singapore biotech mandates.
- Seed closes in 8-12 weeks. Series A with OrbiMed or Pavilion takes 4-6 months with clinical diligence.
- Not for seed, but a provisional US or SG patent application is expected by Series A.
- Not required, but Biopolis presence cuts time to first investor meeting by 6+ months on average.
